Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: A multicenter randomized phase-3 DeCOG trial

Selma Ugurel^*, Carmen Loquai, Patrick Terheyden, Dirk Schadendorf, Erika Richtig, Jochen Utikal, Ralf Gutzmer, Knuth Rass, Cord Sunderkötter, Annette Stein, Michael Fluck, Martin Kaatz, Uwe Trefzer, Katharina Kähler, Rudolf Stadler, Carola Berking, Christoph Höller, Laura Kerschke, Lutz Edler, Annette Kopp-SchneiderJürgen C. Becker

^*Corresponding author for this work

Clinic of Dermatology, Allergology and Venerology

University of Duisburg-Essen
University of Würzburg
Johannes Gutenberg University Mainz
Medizinische Universität Graz
German Cancer Research Center
University of Mannheim
Hannover Medical School
Saarland University
University of Münster
Universitätsklinikum Carl Gustav Carus
Fachklinik Hornheide
Friedrich Schiller University Jena
Charite - Universitatsmedizin Berlin
University of Kiel
Johannes Wesling Klinikum Minden
Ludwig-Maximilians-Universität
University of Vienna

1 Citation (Scopus)

Sort by
Weight
Alphabetically

Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: A multicenter randomized phase-3 DeCOG trial

Fingerprint

Medicine and Dentistry

Immunology and Microbiology